
This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
To own Tenet Healthcare, you really need to buy into its shift toward higher-margin ambulatory care, its willingness to return cash via sizeable buybacks, and its ability to manage a still-elevated debt load. The recent Moody’s upgrade to Ba2 with a stable outlook reinforces that the credit markets are recognizing Tenet’s deleveraging efforts and strong EBITDA, which could ease financing costs and support ongoing investment in outpatient assets. In the short term, that rating action pairs with solid Q1 2026 results and refreshed guidance as key catalysts, especially after a sharp pullback in the share price. At the same time, forecasts for softer earnings in coming years, high leverage and recent insider selling remain central risks, only partially offset by the improved credit profile.
However, investors should not overlook how the high debt load could limit flexibility. Despite retreating, Tenet Healthcare's shares might still be trading above their fair value and there could be some more downside. Discover how much.Explore 4 other fair value estimates on Tenet Healthcare - why the stock might be worth over 2x more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Opportunities like this don't last. These are today's most promising picks. Check them out now:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com